Rigel Pharmaceuticals (RIGL) Set to Announce Earnings on Thursday

Rigel Pharmaceuticals (NASDAQ:RIGL) is scheduled to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect Rigel Pharmaceuticals to post earnings of $0.01 per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.31. The business had revenue of $36.84 million during the quarter, compared to analysts’ expectations of $32.38 million. During the same quarter in the previous year, the business earned ($0.40) EPS. On average, analysts expect Rigel Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rigel Pharmaceuticals Trading Up 3.1 %

Rigel Pharmaceuticals stock opened at $14.50 on Wednesday. The firm has a 50 day simple moving average of $14.52 and a 200 day simple moving average of $11.68. Rigel Pharmaceuticals has a 1-year low of $7.48 and a 1-year high of $17.30. The firm has a market capitalization of $255.13 million, a price-to-earnings ratio of -16.86 and a beta of 0.96.

Analysts Set New Price Targets

A number of analysts recently issued reports on RIGL shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $15.00 price objective on shares of Rigel Pharmaceuticals in a research note on Friday, September 20th. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Rigel Pharmaceuticals in a research report on Friday, October 25th. Finally, StockNews.com upgraded shares of Rigel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 18th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Rigel Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $31.13.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.